Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Operating expenses:
General and administrative	$ 17,920,391	$ 7,653,116
Research and development	7,721,436	3,527,786
In-process research and development (IPR&D) -Teverelix	8,717,475	0
Total operating expenses	34,359,302	11,180,902
Loss from operations	(34,359,302)	(11,180,902)
Other income (expense)
Interest income (expense)	(197,382)	25,386
Loss on SEPA settlements	(278,854)	0
Change in fair value of debentures	(583,823)	0
Loss on extinguishment of debentures	(25,000)	0
Total other income (expense)	(1,085,059)	25,386
Net loss for the year	(35,444,361)	(11,155,516)
Deemed dividend on warrant inducement	(11,837,298)	0
Net loss for the year attributable to common shareholders	(47,281,659)	(11,155,516)
Foreign currency translation adjustment	(10,730)	0
Comprehensive loss for the year attributable to common shareholders	(47,292,389)	(11,155,516)
Net loss attributable to
Common shareholders of the Company	(47,281,513)	(11,155,516)
Non-controlling interests	(146)	0
Comprehensive loss attributable to
Common shareholders of the Company	(47,292,239)	(11,155,516)
Non-controlling interests	$ (150)	$ 0
Net loss per share attributable to common shareholders - basic	$ (2.74)	$ (1.16)
Net loss per share attributable to common shareholders - diluted	$ (2.74)	$ (1.16)
Weighted average number of common shares outstanding - basic	17,283,824	9,619,184
Weighted average number of common shares outstanding - diluted	17,283,824	9,619,184